Periorbital Discoid Lupus Erythematosus

Ghauri, Abdul-Jabbar; Valenzuela, Alejandra A.; O’Donnell, Brett A; Selva, Dinesh; Madge, Simon N.

doi:10.1016/j.ophtha.2012.05.041

Cited by 11 publications

(13 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Discoid lupus-type rash over the eyelids typically appears in the lower eyelid as an irritating, discrete, slightly raised erythematous scaly plaque, which can involve the lid margin and can be complicated by scarring and madarosis 31 37. Lid biopsy and direct immunohistochemistry studies are valuable in confirming the diagnosis.…”

Section: Ocular Manifestationsmentioning

confidence: 99%

See 1 more Smart Citation

Ocular manifestations in systemic lupus erythematosus

2015

View full text Add to dashboard Cite

Section: Ocular Manifestationsmentioning

confidence: 99%

“…Lid biopsy and direct immunohistochemistry studies are valuable in confirming the diagnosis. Topical corticosteroids and oral antimalarial drugs are typically effective 31 37…”

Section: Ocular Manifestationsmentioning

confidence: 99%

Ocular manifestations in systemic lupus erythematosus

2015

View full text Add to dashboard Cite

“…All patients with a diagnosis of DLE should use sunscreens and sunglasses. Because of its favorable efficacy and safety profile, systemic hydroxychloroquine is the preferred first‐line agent for the treatment of DLE 14 . The common use of topical treatments include corticosteroids, calcineurin inhibitors, and intralesional triamcinolone.…”

Section: Discussionmentioning

confidence: 99%

“…The common use of topical treatments include corticosteroids, calcineurin inhibitors, and intralesional triamcinolone. Additional immunosuppressive agents that have been used to treat DLE include oral corticosteroids, methotrexate, retinoids, thalidomide, dapsone, azathioprine, clofazimine, biological agents, and so on 14,15 …”

Section: Discussionmentioning

confidence: 99%

“…We identified 31/41 (75.6%) cases treated with oral antimalarials as a monotherapy (14/41, 34.1%) or in combination with topical corticosteroid or tacrolimus (10/41, 24.4%), intralesional triamcinolone (5/41, 12.2%), systemic corticosteroid (4/41, 9.8%), mycophenolate (1/41, 2.4%), 16 and isotretinoin (1/41, 2.4%) 17 . Twenty‐seven of 31 (87.1%) cases showed an excellent improvement, and some patients under combined therapy only responded well to hydroxychloroquine in the end 7,14 . There was 1/31 (3.2%) report of generalized drug eruption which occurred after about 5 weeks of commencing treatment with quinacrine 4 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Discoid lupus erythematosus solely involving the eyelids: case report and literature review

Wang

et al. 2021

Int J Dermatology

View full text Add to dashboard Cite

Background and Objective The involvement of eyelids occurs in only 5–6% of patients with discoid lupus erythematosus (DLE), commonly with mucocutaneous lesions elsewhere. DLE solely involving the eyelids is relatively rare. This study aimed to describe the clinical features and treatments of all the reported cases of DLE with eyelid involvement as the only symptom. Methods A systematic review was done of all the related literature published both in English and Chinese from May 1, 1984, to March 1, 2020. Only those cases of DLE solely involving eyelids were selected and summarized in two tables. Results (i) DLE solely involving the eyelids is five times more likely to affect females than males. (ii) The majority of cases were presenting with unilateral eyelid involvement. Lower lids, especially both lower lids, were the most commonly affected locations. (iii) An erythematous plaque with scales is the most frequent manifestation. (iv) Approximately 22.9% of the cases had a positive antinuclear antibody (ANA) titer, and the speckled pattern was the most seen. For direct immunofluorescence (DIF), 94.4% of the performed cases showed positive results. (v) More than 85% of these cases showed an excellent response to treatment with oral antimalarials. Conclusion Awareness of this atypical presentation is important to avoid underdiagnosis of DLE solely involving the eyelids. A biopsy for both routine histology and DIF is critical for establishing the diagnosis.

show abstract

Novel role of long non-coding RNAs in autoimmune cutaneous disease

Muntyanu

Ridha

et al. 2021

J. Cell Commun. Signal.

View full text Add to dashboard Cite

Systemic autoimmune rheumatic diseases (SARDs) are a heterogeneous group of chronic multisystem inflammatory disorders that are thought to have a complex pathophysiology, which is not yet fully understood. Recently, the role of non-coding RNAs, including long non-coding RNA (lncRNA), has been of particular interest in the pathogenesis of SARDs. We aimed to summarize the potential roles of lncRNA in SARDs affecting the skin including, systemic sclerosis (SSc), dermatomyositis (DM) and cutaneous lupus erythematosus (CLE). We conducted a narrative review summarizing original articles published until July 19, 2021, regarding lncRNA associated with SSc, DM, and CLE. Several lncRNAs were hypothesized to play an important role in disease pathogenesis of SSc, DM and CLE. In SSc, Negative Regulator of IFN Response (NRIR) was thought to modulate Interferon (IFN) response in monocytes, anti-sense gene to X-inactivation specific transcript (TSIX) to regulate increased collagen stability, HOX transcript antisense RNA (HOTAIR) to increase numbers of myofibroblasts, OTUD6B-Anti-Sense RNA 1 to decrease fibroblast apoptosis, ncRNA00201 to regulate pathways in SSc pathogenesis and carcinogenesis, H19X potentiating TGF-β-driven extracellular matrix production, and finally PSMB8-AS1 potentiates IFN response. In DM, linc-DGCR6-1 expression was hypothesized to target the USP18 protein, a type 1 IFN-inducible protein that is considered a key regulator of IFN signaling. Additionally, AL136018.1 is suggested to regulate the expression Cathepsin G, which increases the permeability of vascular endothelial cells and the chemotaxis of inflammatory cells in peripheral blood and muscle tissue in DM. Lastly, lnc-MIPOL1-6 and lnc-DDX47-3 in discoid CLE were thought to be associated with the expression of chemokines, which are significant in Th1 mediated disease. In this review, we summarize the key lncRNAs that may drive pathogenesis of these connective tissue diseases and could potentially serve as therapeutic targets in the future. KeywordsLncRNA • Systemic sclerosis • Cutaneous lupus erythematosus • Dermatomyositis Background Only 1.2% of RNA encodes messenger RNA (mRNA) that is further translated into proteins (Jarroux et al. 2017). Remaining RNA belongs to a class of non-coding RNA (ncRNA) and includes regulatory RNAs such as Anastasiya Muntyanu and Michelle Le have contributed equally to this work.

show abstract

Periorbital Discoid Lupus Erythematosus

Cited by 11 publications

References 58 publications

Ocular manifestations in systemic lupus erythematosus

Ocular manifestations in systemic lupus erythematosus

Discoid lupus erythematosus solely involving the eyelids: case report and literature review

Novel role of long non-coding RNAs in autoimmune cutaneous disease

Contact Info

Product

Resources

About